Refine by
Pain Relief Articles & Analysis: Older
201 news found
In the ever-evolving pharmaceutical landscape, CD Formulation is emerging as a pioneer in the development of oral thin film (OTF) delivery systems. These cutting-edge drug delivery technologies enhance therapeutic efficiency and patient compliance, offering a versatile alternative to conventional tablets and capsules. CD Formulation specializes in providing comprehensive contract development and ...
At best, most of us tolerate needles. Whether a vaccine, an IV drip, or a blood draw, we can talk ourselves through it with the knowledge that it is for the greater good and will only cause temporary discomfort. On the other side of the spectrum, there are people with such an intense fear of needles that they are considered to have a phobia, trypanophobia to be precise. Many articles have been ...
In a groundbreaking development in the field of pharmaceuticals, CD Formulation, a prominent drug formulation company, has announced the launch of Oral Thin Film Technology. This cutting-edge drug delivery system is poised to revolutionize medication administration, offering patients a more convenient and effective treatment method. Oral Thin Film Technology is a user-friendly drug delivery ...
Have you heard of the sensory phenomenon known as ASMR for sleep? ASMR stands for autonomous sensory meridian response, a condition, experience, or phenomenon that helps you fall asleep. As a form of parasthesia (a group or series of sensations felt in the skin), ASMR is perceived as a pleasant experience that is characterized by a tingling sensation in the neck and scalp areas that are ...
January’s Journal of Neurosurgery (JNS) published a series of 17 videos that examine the application of exoscopic visualization in cerebrovascular, neuro-oncologic, pediatric, peripheral nerve, and spinal neurosurgery. The video series highlights the exoscope as a versatile alternative to traditional optical microcopy. Seven of the videos highlight the use of Synaptive’s robotic ...
Cebranopadol is the first and only dual nociceptin/orphanin FQ peptide (NOP) receptor and µ-opioid peptide (MOP) receptor agonist (dual-NMR) analgesic in clinical development for the treatment of moderate to severe pain, as well as opioid use disorder (OUD). Clinical studies to date suggest that the first-in-class dual-NMR analgesic has the potential to become the first ...
This alkaloid is a powerful narcotic used for the relief of pain. Other well-known alkaloids used in clinical settings include strychnine, quinine, ephedrine, and ...
Thomas Englese, a 20+ year industry veteran with a track record of success at leading biopharmaceutical companies, joins as chief commercial officer Marc Lesnick, Ph.D., appointed as chief development officer, bringing more than 20 years of experience in multiple therapeutic areas Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company focused on ADHD, pain and neurological ...
Recently, the Ministry of Industry and Information Technology, the National Health Commission and other 17 departments jointly issued the "robot" application action implementation plan to encourage the development of surgery, auxiliary examination, auxiliary rounds, intensive care, rehabilitation and other medical robot products, "robot The "robot" has ushered in a new round of development ...
Patent provides protection for High Frequency Spinal Cord Stimulation with Beat Technology Vancouver, Washington – March 20, 2015 – Meagan Medical Inc., a clinical research and medical device development company focused on investigating and developing optimal ways of managing and controlling pain, announced today the issuance of a key patent related to a unique ...
A new study published in Proceedings of the National Academy of Sciences (PNAS) indicates, “Delta opioid receptors have a built-in mechanism for pain relief and can be precisely targeted with drug-delivering nanoparticles, making them a promising target for treating chronic inammatory pain with fewer side eects.” Researchers used ...
Study evaluating human abuse potential demonstrates that the likeability of cebranopadol administered orally in nondependent recreational opioid users was significantly less as compared to immediate release (IR) formulations of either tramadol or oxycodone, suggesting a lower potential for abuse versus traditional C-II and C-IV opioids A first-in-class investigational analgesic uniquely ...
Lumosa's Naldebain(R) injection, an analgesic that offers up to 7 days of pain relief, was one of few medicines that received international market authorization; other drugs with this status include PharmaEngine's Onivyde(R), PharmaEssentia's Besremi(R), and Panion & BF Biotech's ...
electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that gammaCore Sapphire has been issued a National Code Number (CNK) in Belgium. CNK numbers are unique product code identifiers allocated by the Belgian Pharmaceutical Association (APB) for products and medicines commercially available from pharmacies throughout ...
Galapagos NV (Euronext & NASDAQ: GLPG) will present new data on filgotinib at the American College of Rheumatology (ACR) Convergence 2022 meeting taking place in Philadelphia, Pennsylvania from 10-14 November 2022. Dr. Walid Abi-Saab, Chief Medical officer, at Galapagos said, “We are excited to present data at ACR which highlights our continued commitment to patients and the healthcare ...
The biggest difference between spinal blocks vs epidurals is their amount of pain relief: spinal blocks provide total pain relief, while epidurals provide partial pain relief. ...
electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that gammaCore Sapphire™, the first and only FDA-cleared, non-invasive device to treat and prevent multiple types of headache pain via the vagus nerve, will be distributed and billed exclusively by Joerns Healthcare, LLC (Joerns) within selected managed care health systems. ...
Gesynta Pharma AB today announces the decision to advance the development of its clinical-stage drug candidate GS-248 in endometriosis - a chronic inflammatory condition affecting approximately 10 percent of all women of reproductive age. This strategically important decision follows a recent preclinical proof-of-concept study with GS-248 in an advanced model of endometriosis, where ...
Bexson Biomedical, Inc., a biopharmaceutical company focused on disrupting the small molecule injectable market and enabling home health solutions, today announced the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Application No. 17/546,880 filed on December 9, 2021 and titled Complexing Agent Salt Formulations of Pharmaceutical Compounds. Bexson’s ...
Active Implants, LLC, a developer of orthopedic implant solutions for joint preservation, today announced that the NUsurface® Meniscus Implant has been granted a Breakthrough Device Designation from the U.S. Food and Drug Administration. The NUsurface® Meniscus Implant is the first “artificial meniscus” to be marketed in Europe and, if cleared by the FDA, would be the first ...